Delivery Order 36F79719D0108-36C26124N0562
Award Date
4/5/24
Potential Completion Date
5/6/24
Potential Value
$21K
Federal Agency
Veterans Integrated Service Network 21
Awardee
Amicus Therapeutics US, LLC
Ultimate Awardee
Amicus Therapeutics, Inc.
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Philadelphia, PA 19104, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Veterans Affairs Veterans Health Administration awarded a firm fixed price delivery order to Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc., for the specialty medication Galafold (migalastat) to treat Fabry disease. The $21,089.47 award was placed against Amicus Therapeutics, Inc.'s Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule contract with the General Services Administration, which provides a mechanism for federal agencies to procure...
The U.S. Department of Veterans Affairs (VA) awarded a $21,089.47 firm fixed price delivery order contract to Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc. The contract is for the supply of GALAFOLD 123 MG, an enzyme replacement therapy for the treatment of Fabry disease. This delivery order was placed under Amicus Therapeutics US, LLC's Federal Supply Schedule (FSS) contract 36F79724D0185, which has a ceiling value of $13,024,630 and a period of performance through...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 9 awarded a $60,374.73 delivery order to Amicus Therapeutics US, LLC under the company's Pharmaceuticals and Drugs Federal Supply Schedule contract. The one-month order is for an emergency purchase of Galifold, a medication used to treat adult patients with a rare disease called Fabry disease. As the lead agency serving veterans, the VA aims to ensure former military personnel and their families...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 9 awarded a $18,520.05 delivery order to Amicus Therapeutics US, LLC under the Pharmaceuticals and Drugs Federal Supply Schedule contract. The delivery order is for GALAFOLD specialty medication migalastat 123 mg to treat Fabry disease and will be fulfilled by Amicus Therapeutics, Inc., the parent company of Amicus Therapeutics US, LLC, with place of performance in Cranbury, New Jersey. The...
This is a $21,089.47 firm fixed price delivery order issued by the Department of Veterans Affairs (VA) to Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc. The contract is for the pharmaceutical product Galafold 123 mg, an FDA-approved enzyme replacement therapy used to treat Fabry disease. This delivery order is placed against Amicus Therapeutics US, LLC's Pharmaceuticals and Drugs Federal Supply Schedule contract (FSS-61-IB) with the General Services Administration. The...
The Department of Veterans Affairs Veterans Health Administration (VHA) awarded a firm fixed-price delivery order to Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc., to provide the specialty medication GALAFOLD 123 MG. This delivery order, valued at $21,089.47, is being issued under the General Services Administration's Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule contract. Amicus Therapeutics US, LLC has previously been awarded multiple delivery orders...
This federal contract award is for the delivery of GALAFOLD 123 MG to the Department of Veterans Affairs (VA). The contract was awarded to Amicus Therapeutics US, LLC, a subsidiary of the biopharmaceutical company Amicus Therapeutics, Inc. The $21,089.47 firm fixed price delivery order has a completion date of November 19, 2024 and was awarded on November 14, 2024. Amicus Therapeutics US, LLC holds a Federal Supply Schedule (FSS) contract (36F79724D0185) with the VA's Pharmaceuticals and Drugs...
This is a federal contract award to Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc., for the delivery of Galafold (migalastat), an enzyme replacement therapy used to treat Fabry disease. The contract, valued at $261,090.68, is a firm-fixed-price delivery order awarded by the U.S. Department of Veterans Affairs (VA) under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The contract has an ultimate completion date of November 14, 2025. Amicus...
This federal contract award was issued by the U.S. Department of Veterans Affairs (VA) to Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc. The contract is a $21,089.47 firm fixed price delivery order for the supply of Galafold (migalastat), an FDA-approved enzyme replacement therapy used to treat Fabry disease, a rare genetic disorder. The contract has an ultimate completion date of October 7, 2024 and was awarded on October 3, 2024. The contract is not set aside and Amicus...
This is a firm fixed-price delivery order awarded by the Department of Veterans Affairs (VA) through the Veterans Integrated Service Network 9 (VISN 9) to Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc. The $18,888.46 order is for the supply of Galafold (migalastat), an FDA-approved enzyme replacement therapy used to treat Fabry disease, a rare genetic disorder. The order was placed against Amicus Therapeutics US, LLC's Pharmaceuticals and Drugs Federal Supply Schedule...